160,985 Shares in Arrowhead Pharmaceuticals, Inc. $ARWR Acquired by Universal Beteiligungs und Servicegesellschaft mbH

Universal Beteiligungs und Servicegesellschaft mbH purchased a new stake in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 160,985 shares of the biotechnology company’s stock, valued at approximately $5,552,000. Universal Beteiligungs und Servicegesellschaft mbH owned 0.12% of Arrowhead Pharmaceuticals as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors also recently bought and sold shares of the company. CWM LLC increased its position in shares of Arrowhead Pharmaceuticals by 6.7% in the third quarter. CWM LLC now owns 12,179 shares of the biotechnology company’s stock worth $420,000 after acquiring an additional 764 shares in the last quarter. Resona Asset Management Co. Ltd. increased its holdings in Arrowhead Pharmaceuticals by 8.7% in the 2nd quarter. Resona Asset Management Co. Ltd. now owns 11,218 shares of the biotechnology company’s stock valued at $180,000 after purchasing an additional 900 shares in the last quarter. Salomon & Ludwin LLC purchased a new position in Arrowhead Pharmaceuticals in the third quarter valued at about $34,000. Empowered Funds LLC lifted its stake in shares of Arrowhead Pharmaceuticals by 6.9% during the first quarter. Empowered Funds LLC now owns 15,252 shares of the biotechnology company’s stock worth $194,000 after purchasing an additional 979 shares in the last quarter. Finally, GAMMA Investing LLC boosted its position in shares of Arrowhead Pharmaceuticals by 64.4% in the third quarter. GAMMA Investing LLC now owns 2,626 shares of the biotechnology company’s stock worth $91,000 after buying an additional 1,029 shares during the period. 62.61% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several brokerages recently commented on ARWR. Chardan Capital raised their target price on Arrowhead Pharmaceuticals from $60.00 to $80.00 and gave the company a “buy” rating in a report on Wednesday, January 7th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Arrowhead Pharmaceuticals in a research report on Wednesday, January 21st. The Goldman Sachs Group boosted their target price on shares of Arrowhead Pharmaceuticals from $50.00 to $85.00 and gave the stock a “neutral” rating in a research report on Wednesday, January 7th. Royal Bank Of Canada upped their target price on shares of Arrowhead Pharmaceuticals from $52.00 to $80.00 and gave the company an “outperform” rating in a research note on Thursday, December 11th. Finally, Morgan Stanley lifted their price target on shares of Arrowhead Pharmaceuticals from $48.00 to $81.00 and gave the stock an “equal weight” rating in a research note on Wednesday, January 7th. One investment analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Arrowhead Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus price target of $81.67.

Arrowhead Pharmaceuticals Trading Down 0.3%

Shares of ARWR stock opened at $66.82 on Tuesday. The stock has a market cap of $9.08 billion, a price-to-earnings ratio of -835.15 and a beta of 1.21. The company has a debt-to-equity ratio of 0.43, a quick ratio of 4.86 and a current ratio of 4.86. Arrowhead Pharmaceuticals, Inc. has a 52-week low of $9.57 and a 52-week high of $76.76. The firm has a fifty day moving average of $62.95 and a 200-day moving average of $40.59.

Insiders Place Their Bets

In related news, insider James C. Hamilton sold 40,164 shares of Arrowhead Pharmaceuticals stock in a transaction dated Monday, January 5th. The stock was sold at an average price of $63.11, for a total value of $2,534,750.04. Following the completion of the transaction, the insider directly owned 171,958 shares of the company’s stock, valued at $10,852,269.38. The trade was a 18.93% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Michael S. Perry sold 16,250 shares of the firm’s stock in a transaction that occurred on Friday, December 5th. The shares were sold at an average price of $61.03, for a total transaction of $991,737.50. Following the completion of the transaction, the director directly owned 115,240 shares in the company, valued at approximately $7,033,097.20. The trade was a 12.36% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last 90 days, insiders have sold 510,836 shares of company stock worth $33,603,060. 4.30% of the stock is owned by company insiders.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Since its founding in 2008, Arrowhead has leveraged its proprietary delivery platform—known internally as the Advanced RNAi Compound (ARC) technology—to silence disease-causing genes in patients suffering from genetically defined diseases. The company’s approach aims to offer durable, targeted treatments across a range of therapeutic areas.

The company’s pipeline includes multiple candidates in various stages of development.